You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥-B(01672.HK):上海市公共衞生臨牀中心啟動抗PD-L1抗體ASC22(恩沃利單抗)聯合西達本胺在HIV感染者中實現功能性治癒的研究
格隆匯 02-14 17:03

格隆匯2月14日丨歌禮制藥-B(01672.HK)宣佈,由上海市公共衞生臨牀中心發起的抗PD-L1抗體ASC22(恩沃利單抗)聯合西達本胺在抗病毒抑制的艾滋病病毒(HIV)感染者中實現功能性治癒研究啟動。

該研究(臨牀試驗註冊編號:NCT05129189)旨在評估ASC22(恩沃利單抗)聯合西達本胺在HIV感染者中對被感染的潛伏期細胞病毒儲存庫的作用。歌禮生物科技(杭州)有限公司和深圳微芯生物科技股份有限公司分別提供本次臨牀試驗的ASC22和西達本胺。

該試驗用藥方案為每四周一次皮下注射1 mg/kg ASC22(恩沃利單抗)聯合每週兩次每次口服10 mg西達本胺片,為期12周。

ASC22(恩沃利單抗)是一種皮下注射的PD-L1單域抗體,具有重建如乙型肝炎病毒(HBV)和HIV等慢性病毒感染患者的病毒特異性免疫功能的潛力。

HIV感染的潛伏期細胞是治癒HIV的關鍵障礙。最新研究1表明,在臨牀試驗中,阻斷PD-1/PD-L1通路可逆轉HIV潛伏期。這項研究支持PD-1/PD-L1抗體聯合其他藥物以減少HIV感染的潛伏期細胞內病毒儲存庫的治療策略。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account